The Bristol Myers Squibb-backed oncology drug developer ultimately raised nearly $144m in its initial public offering.
Ikena Oncology, a US-based cancer therapy developer backed by pharmaceutical firm Bristol Myers Squibb (BMS), has closed its initial public offering at almost $144m.
The company had issued more than 7.81 million shares priced at $16.00 each last month, and they doubled in price to $32.00 by the end of their first day of trading.
Joint book-running managers Jefferies, Cowen, Credit Suisse and William Blair subsequently bought about 1.17 million additional shares to close the offering.
Ikena is working on…
